Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2019 Jul 17

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2019 Jul 17

DOI: 10.23736/S0026-4806.19.06236-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in treating diffuse large B-cell lymphoma

Yuhuan GAO 1, Yan XIE 2, Lihong LIU 1, Hongwei XUE 3, Ming HOU 4, Mingzhi ZHANG 5, Zeping ZHOU 6, Pengxiang GUO 7, Hongxia YAO 8, Zonghong SHAO 9, Xiaobao XIE 10, Jun ZHU 2

1 Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 2 Department of Lymphoma Medicine, Beijing Cancer Hospital, Beijing, China; 3 Department of Oncology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, China; 4 Department of Hematology, Qilu Hospital, Shandong University, Jinan, China; 5 Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 6 Department of Hematology, Second Affiliated Hospital of Kunming Medical University, Kunming, China; 7 Department of Hematology, Guizhou People's Hospital, Guizhou, China; 8 Department of Hematology, Hainan Provincial People's Hospital, Hainan, China; 9 Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China; 10 Department of Hematology, Changzhou First People's Hospital, Changzhou, China


PDF


inizio pagina